News

Thermosome receives BfArM approval

Big congratulations to our portfolio company Thermosome on the approval by the German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible ethics committee to conduct a phase 1 trial with its lead program THE001 in patients with soft tissue sarcoma.

THE001 is a thermosensitive liposomal formulation of the chemotherapeutic drug doxorubicin (DPPG2-TSL-DOX).
It has a different mode of action than conventional liposomes which enables intravascular drug release initiated by a mild heat trigger using clinically established hyperthermia devices. This results in up to 15-fold higher local drug concentrations and improves efficacy by creating a local boost at the desired site of action.

We keep our fingers crossed and hope that this approach will quickly find its way to patients.

More information in the press release under the following Link

More about Themosome

adivo starts clinical study Overview Hemotune launches feasibility project with AstraZeneca
Want to learn more about OCCIDENT?

News

About

OCCIDENT’s End-of-Year Message

As Science Investor, we build bridges of various kinds, over­coming challenges and bridging differences, thus connecting different worlds and perspectives.